Search details
1.
The CLIP1-LTK fusion is an oncogenic driverĀ in non-small-cell lung cancer.
Nature
; 600(7888): 319-323, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34819663
2.
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Int J Clin Oncol
; 28(1): 79-88, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36414827
3.
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
Int J Clin Oncol
; 28(10): 1354-1368, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37548831
4.
Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.
Cancer Sci
; 113(1): 287-296, 2022 Jan.
Article
in English
| MEDLINE | ID: mdl-34689382
5.
Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
Invest New Drugs
; 40(1): 106-114, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34495421
6.
Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR).
Cancer Sci
; 112(1): 388-396, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-33185928
7.
Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases.
Invest New Drugs
; 39(6): 1598-1603, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34215931
8.
A randomized phase 3 study of maintenance therapy with S-1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L).
Cancer
; 126(16): 3648-3656, 2020 08 15.
Article
in English
| MEDLINE | ID: mdl-32484914
9.
Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Cancer
; 126(9): 1940-1948, 2020 01 01.
Article
in English
| MEDLINE | ID: mdl-32022929
10.
Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial.
Invest New Drugs
; 38(6): 1854-1861, 2020 12.
Article
in English
| MEDLINE | ID: mdl-32424780
11.
Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
Jpn J Clin Oncol
; 49(7): 671-675, 2019 Jul 01.
Article
in English
| MEDLINE | ID: mdl-30920616
12.
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.
Int J Clin Oncol
; 24(7): 731-770, 2019 Jul.
Article
in English
| MEDLINE | ID: mdl-31049758
13.
Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
Int J Clin Oncol
; 28(10): 1369-1370, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37684530
14.
[Effectiveness of Nivolumab in Large-Cell Neuroendocrine Carcinoma of the Lung - A Report of Two Cases].
Gan To Kagaku Ryoho
; 44(1): 59-62, 2017 Jan.
Article
in Japanese
| MEDLINE | ID: mdl-28174381
15.
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
Cancer
; 122(7): 1050-9, 2016 Apr 01.
Article
in English
| MEDLINE | ID: mdl-26828788
16.
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 16(16): 1630-8, 2015 Dec.
Article
in English
| MEDLINE | ID: mdl-26522337
17.
Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA.
Clin Chem
; 61(9): 1191-6, 2015 Sep.
Article
in English
| MEDLINE | ID: mdl-26206882
18.
A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
Jpn J Clin Oncol
; 44(9): 868-71, 2014 Sep.
Article
in English
| MEDLINE | ID: mdl-25028698
19.
[Evaluation of recurrence rates on change in hormone receptor and human epidermal growth factor receptor 2 status after neo-adjuvant chemotherapy in breast cancer patients].
Gan To Kagaku Ryoho
; 41(3): 313-6, 2014 Mar.
Article
in Japanese
| MEDLINE | ID: mdl-24743275
20.
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 10(3): 315-324, 2024 Mar 01.
Article
in English
| MEDLINE | ID: mdl-38127362